Key facts
- It has raised $30K; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Bilgiyi Ticarileştirme Merkezi, Eyşan Öztürk, Mukadder Tavşancı, Sabancı ARF, Techventure VC — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for RareSum
- ·The full record, as it builds
Funding rounds
No funding rounds for RareSum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RareSum
Operator of a healthcare company intended to improve rare disease diagnostics within the healthcare sector. The company offers AI-powered decision support tools designed to assist physicians in diagnosing patient cases, increasing suspicion and driving physicians to relevant testing for early diagnosis, enabling doctors to reduce research time and provide the most relevant results for each specific patient, rather than providing general data.
- Sector
- Healthcare
- HQ
- Istanbul, Turkey
- Founded
- 2024
- Employees
- 6
- Website
- raresum.com/
- Ownership
- Privately Held (backing)
RareSum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RareSum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RareSum in its N-PORT filings yet. We sweep new filings monthly.